Marc Cohen-Renée LarocqueGlobal Health Research InitiativeAfri-Can Forum, January 18, 2013-Entebbe, Uganda

The Global Health Research Initiative - GHRI

AGENDA• The Global Health Research Initiative (GHRI)• GHRI programs• Overview of the Canadian HIV Vaccine

Initiative (CHVI)• GHRI and CHVI – where is the link?• Q&A

GHRI was founded in 2001. It is a partnership of three Canadian government agencies:

• Canadian Institutes of Health Research (CIHR)• Canadian International Development Agency

(CIDA)• International Development Research Centre

(IDRC) IDRC is the “host” agency

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

GHRI grants support 3 complementary areas of action:• research (a range of multi-disciplinary

approaches, including action-research, participatory research, RCTs, etc.)

• strengthening research capacity (learning-by-doing)

• knowledge translation (teams with decision-makers)

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

GHRI: 2001-2016Where we work

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

GHRI Programs

Africa Health System Initiative-

RES

$26.6M2006-2012

Teasdale-Corti$16.7M2009-2014

$1.055M2008-2013

CIII-Haiti

$5.9M

2008-2014

$4M

EcoEID in SE Asia

GHRI contribution2010-2013

HIV/AIDS Prevention

Trials Capacity Building

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

Ecohealth Emerging Infectious Diseases Program in Southeast Asia• 3 projects• 7 countries• 2010-2013• 4M$ GHRI

contribution Where we work

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

African Health Systems Initiative – Support to African Research Partnerships• 10 projects• 7 countries• 2008-2014• 5.9M$

Where we work

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

HIV/AIDS Prevention Trials Capacity Building Grants, phase II• 9 projects• 30 countries• 2009-2014• 16.7M$

Where we work

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

HIV/AIDS Prevention Trials Capacity Building Grant Phase2• Program offered in partnership with the Canadian

HIV Vaccine Initiative (CHVI) through a financial contribution from the Canadian International Development Agency (CIDA) and the International Development Research Centre (IDRC)

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

The Canadian HIV Vaccine Initiative (CHVI)

• Government of Canada (CIDA, CIHR, HC, IC, PHAC) and Bill & Melinda Gates Foundation partnership

• Initiated in 2007 to help accelerate efforts to develop a safe, effective, affordable and globally accessible HIV vaccine

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

• CHVI objectives are:

• To advance the basic science of HIV vaccine in Canada, and low-and-middle-income countries

• To support the translation of basic sciences discoveries into clinical trials

• To address the enabling conditions (regulatory, community)

• To advance the development of related technologies• To improve the efficacy and effectiveness of HIV

Prevention of Mother-to-Child (PMTCT) services in low-and-middle-income countries

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

CHVI

Advance the basic sciences of HIV

Translation of sciences discoveries in clinical trial

CIHR grants GHRI/CIDA grants

CIHR PHAC CIDA IC HC

ACO

Bill and Melinda Gates Foundation

Team Grant: HIV/AIDS Vaccine Discovery and

Social Research

5 Projects

GHRI HIV Prevention Trials Capacity Building

Grants

9 Projects

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

Newsletter: Third issueGHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

Booklet… available today!GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

Thank you

Overview of CHVI Program Overview Collaboration Lessons Q&A

Questions?

GHRI GHRI Programs Overview of CHVI GHRI-CHVI? Q&A

Program objectives• Strengthen the capacity and leadership skills of

African researchers and institutions to undertake prevention trials with special focus on innovations in HIV/AIDS prevention, particularly HIV vaccines

• Support collaboration and networking of African researchers and research users in HIV/AIDS prevention trials related research and policy development

• Advance the collaboration and networking of Canadian and African researchers and institutions in global HIV/AIDS prevention trials efforts

Overview of CHVI Program Overview Collaboration Lessons Q&A

Program Design• Belongs to: CHVI objective to support the

translation of basic science discoveries into clinical trials

• African-led research teams • Grants: up to CA$1.8M over 4 years• Comprehensive approach to strengthening

research capacity: trial administration and management, ethics reviews processes, securing funding, engaging communities and policy-makers, publishing results

Overview of CHVI Program Overview Collaboration Lessons Q&A

Complementary grants• Up to CA$50 000 to support scientific

excellence in HIV prevention research and capacity building of young researchers through learning-by-doing• KAVI

O. Anzala, Nadia Musimbi Chanzu• CANSSA

• S. Allen, T. Ndung’u, William Kilembe, Mammekwa Mokgoro• CAPT

• D. Wilson, L. Balfour, P. Kaleebu, B. Cameron, Rusha Govender, George Miiro

• Nigeria• A. Abimiku, G. Garber, K. Corace, Susan Yilme

• TanZamBo• R. Musonda, M. Wainberg, Simani Gaseitsiwe, Balthazar Nyombi, Mike

Chaponda

Overview of CHVI Program Overview Collaboration Lessons Q&A

Project teams build capacities in:• Good Clinical Practice• Laboratory techniques• Social and Biomedical Sciences• Regulatory processes• Advocacy

Project teams use different approaches • Short and long term trainings• Mentoring• Learning by doing

Project teams audiences include• Researchers• Decison-makers• Communities and media

Overview of CHVI Program Overview Collaboration Lessons Q&A

CIHR Programmatic Grants to tackle health and health equity• Yassi, Engelbrecht (Workplace South-Africa)

“This GHRI-funded project was likely an important factor in leveraging a 5-year research programmatic grant from CIHR (Health Equity program) for our collaborative team, and the

partnerships forged during this GHRI initiative will be crucial in the operationalizing of this research program”.

Yassi A., Engelbrecht M., First Annual Report, 2011

• Alary, Zannou (BENIN)

Overview of CHVI Program Overview Collaboration Lessons Q&A

Projects teams

1. The Kenya AIDS Vaccine Initiative (KAVI): A Centre of Excellence for HIV Vaccine/Prevention Trials in East Africa-KENYA

2. Canada-Africa Prevention Trials (CAPT) Network – Proposal to Build African Capacity for HIV/AIDS Prevention Trials-UGANDA, SOUTH AFRICA, KENYA

3. TanZamBo Capacity Building for HIV Prevention Research Network-BOTSWANA, TANZANIA, ZAMBIA

Overview of CHVI Program Overview Collaboration Lessons Q&A

Projects teams

4. ADAPT2 (African Development of AIDS Prevention Trials capacities, second phase)-SOUTH AFRICA, NAMIBIA, BOTSWANA, LESOTHO, MALAWI, MOZAMBIQUE, SWAZILAND, TANZANIA, ZAMBIA, ZIMBABWE

5. West African Platform for HIV Intervention Research (WAPHIR)-SENEGAL, THE GAMBIA, GUINEA BISSAU

6. The Canada – sub-Saharan Africa (CANSSA) HIV/AIDS network: Building capacity for prevention trials research and clinical care in Africa- SOUTH AFRICA

Overview of CHVI Program Overview Collaboration Lessons Q&A

Projects teams

7. Creating a common platform for HIV vaccine research and HIV care and treatment program- NIGERIA

8. Closed: Preparing for HIV prevention randomized control trials- BENIN

9. Closed: Building capacity for HIV prevention trials in the health care workplace- SOUTH AFRICA

Overview of CHVI Program Overview Collaboration Lessons Q&A

Canada-Africa Prevention Trials Network• Assist in developing 8 African HIV prevention

research centres• Build sustainable

leadership through training opportunities• Provide internal

communications and facilitation of collaborativeresearch initiatives

Kenya AIDS Vaccine Initiative (KAVI)• Establish a Centre of excellence for training

health care professionals in East Africa on vaccine trials

• Enhance lab capacity and capacity of local REBs/institutional administrators to handle vaccine development

• Build vaccine literacy/acceptance among local communities, policy makers and other stakeholders

African Development of AIDS Prevention Trials (ADAPT2)• Increase capacity to conduct HIV prevention

trials in SADC countries through short methods courses

• Apply multi-country RCT logisticalframework; build capacity to train students in methodology

• Increase capacity of African decision-makers to use research

Canada-sub-Saharan Africa HIV/AIDS network (CANSSA)• African HIV/AIDS network of excellence• Knowledge translation and training in clinical,

biomedical and sociological research• Clinical and laboratory infrastructure and

establishment of pilot projects

West African Platform for HIV Intervention Research (WAPHIR)• Strengthen lab capacity

through improved immunology/virology techniques, and a clinicaltrial support training program with a lab platform

Nigeria team• Creation of internationally certified HIV clinical

research site• Ability to conduct HIV vaccine clinical trials at

the highest standard and build supportive lab capacity

• Build capacity in:• clinical, research ethics, regulation • community mobilization, risk cohort development • vaccine cohort development

TanZamBo Capacity Building for HIV Prevention Research Network (TanZamBo)• Capacity building of researchers to conduct

HIV/AIDS prevention trials and research, including vaccines

• Institutional capacity building, improving expertise and technology

• Support for MSc training in clinical research/biostatisticsand postdocs who manage the projects with PIs

Benin – Preparing for HIV prevention randomized control trials- Closed• Capacity building for Bénin PhD students in

Québec• Maintaining l'Unité de Recherche en

Prévention du VIH (UREPIV), Université d'Abomey-Calavi, to support researchers and community workers

• Maintaining sex worker cohort in Cotonou

South Africa – Building capacity for HIV prevention trials in the health care workplace-Closed• Certificate program to

train health care workers in research

• design, implementation and evaluation of workplace-based interventions for HIV & TB prevention